Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The descending serotonergic pathway is a major component of the endogenous pain-control system that originates in the brainstem, primarily within the rostral ventromedial medulla (RVM) and the nucleus raphe magnus, and projects to the dorsal horn of the spinal cord (1). This pathway acts as a physiological rheostat for pain, capable of either inhibiting (antinociception) or facilitating (pro-nociception) the transmission of nociceptive signals from the periphery to the brain, depending on the specific serotonin receptor subtypes activated (2). Serotonin (5-HT) released in the spinal cord can activate inhibitory 5-HT1A receptors to reduce pain or excitatory 5-HT2 and 5-HT3 receptors to enhance pain perception (3). Pharmacological intervention often focuses on enhancing the inhibitory component of this pathway, using serotonin-norepinephrine reuptake inhibitors (SNRIs) or tricyclic antidepressants to treat chronic and neuropathic pain conditions (4). Dysregulation of this system is a hallmark of centralized pain syndromes such as fibromyalgia, where the normal inhibitory tone of the descending pathway is diminished or the facilitatory tone is pathologically increased (5). Sources: (1) https://www.ncbi.nlm.nih.gov/books/NBK539789/; (2) https://pubmed.ncbi.nlm.nih.gov/11972960/; (3) https://www.nature.com/articles/nrn.2016.121; (4) https://pubmed.ncbi.nlm.nih.gov/20857038/; (5) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107914/.
Drugs targeting this pathway typically act by inhibiting the reuptake of serotonin (via SERT) or norepinephrine (via NET) in the spinal cord, thereby increasing the concentration of these neurotransmitters at the synapse to enhance descending inhibition of pain signals. Some agents also act as direct agonists or antagonists at specific serotonergic receptor subtypes (e.g., 5-HT1, 5-HT3) within the spinal dorsal horn.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Descending serotonergic pathway (DSP).